Numerion Labs

About Numerion Labs

Financials

Dated, source-cited figures. Estimates are marked.

Products by Numerion Labs

All products by Numerion Labs reviewed by our AI panel of experts.

AtomwiseMachine Learning Platforms

AI-powered small molecule drug discovery platform

Free7.3/10

How Our Review Panel Scores Numerion Labs

Six independent reviewer personalities assessed Numerion Labs's product on their own terms. They disagreed by 2.2 points — The Skeptic was the hardest to convince, The Domain Strategist the most positive.

Averaged across 1 reviewed product in our catalog. Scores are out of 10.

Competitive Landscape

Who Numerion Labs competes with, and how they differ.

Recursion7.4/10

Recursion built a large-scale phenomics (automated cell-imaging) platform and, after absorbing Exscientia in November 2024, added in-house automated chemistry synthesis and a multi-program clinical pipeline -- a fully integrated, better-capitalized rival to Numerion's smaller AtomNet-licensing model.

1 product reviewed on TopReviewed

Insilico Medicine7.7/10

Insilico Medicine runs an end-to-end generative-AI-to-clinic pipeline (Pharma.AI) and already has self-discovered molecules such as ISM001-055 in Phase II trials, while Numerion still mostly licenses AtomNet screening into partners' pipelines rather than running its own clinical-stage assets.

1 product reviewed on TopReviewed

I

Isomorphic Labs

Isomorphic Labs, DeepMind's drug-discovery spinout led by Demis Hassabis, builds on AlphaFold's structure-prediction lineage and has raised $600M with pharma partnerships including Eli Lilly -- direct overlap with Numerion's own Lilly collaboration but backed by far deeper AI-research resources.

Company Timeline

Key milestones in Numerion Labs's history, with sources.

1. Oct 29, 2025Milestone

   Rebrands as Numerion Labs, unveils APEX screening protocol with NVIDIA

   Atomwise announced it is now Numerion Labs and published APEX (Approximate-but-Exhaustive Search), co-authored with NVIDIA researchers, which screens billion-compound virtual libraries in seconds.

   prnewswire.com
2. Feb 18, 2025Funding

   Series C — $45M; Steve Worland named CEO

   Atomwise raised a $45M Series C, smaller than its 2020 Series B, and appointed industry veteran Steve Worland as CEO, succeeding founding CEO Abraham Heifets.

   endpoints.news
3. October 2024Milestone

   Founding CEO Abraham Heifets departs after 12 years

   Endpoints News reported that Atomwise founding CEO and co-founder Abraham Heifets left the company after leading it for a dozen years; the departure was not announced publicly by the company.

   endpoints.news
4. December 2022Milestone

   Cuts 30% of staff, pivots from partnerships to internal pipeline

   Months after a $1.2B Sanofi partnership, Atomwise laid off about 30 people (~30% of staff) and shifted strategy from signing pharma partnerships toward advancing its own drug candidates, starting with a TYK2 inhibitor.

   endpoints.news
5. Aug 11, 2020Funding

   Series B — $123M co-led by B Capital Group and Sanabil Investments

   Atomwise closed an oversubscribed $123M Series B, bringing total capital raised to almost $175M, with returning backers DCVC, Tencent and Y Combinator.

   enlightenbio.com
6. Jun 3, 2019Partnership

   Multi-year AI drug discovery agreement with Eli Lilly

   Atomwise signed a multi-year, multi-target agreement with Eli Lilly to apply its AtomNet AI platform to preclinical drug discovery across up to 10 targets, worth up to $560M in potential milestones.

   biospace.com
7. Mar 7, 2018Funding

   Series A — $45M led by Monsanto Growth Ventures, B Capital Group and Data Collective

   Atomwise raised a $45M Series A round, bringing total capital raised to more than $51M, to grow its AtomNet AI drug-discovery platform.

   biospace.com
8. Jun 3, 2015Funding

   Y Combinator-backed seed round — $6M

   Following Y Combinator's Winter 2015 batch, Atomwise raised a $6M seed round led by Data Collective, with DFJ and Khosla Ventures participating, to fund AtomNet model training and hiring.

   venturebeat.com
9. 2012Founded

   Founded as Chematria by Abraham Heifets and Izhar Wallach

   Abraham Heifets and Izhar Wallach, then PhD researchers at the University of Toronto, founded the company in 2012 as Chematria, later renaming it Atomwise to emphasize AtomNet's atom-level deep learning approach.

   venturebeat.com